Abstract
GS-008 - A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
